Santhera Pharmaceuticals Holding AG
Hammerstrasse 49
CH-4410 Liestal / Switzerland
Phone +41 61 906 89 50
Fax +41 61 906 89 51
www.santhera.com

Santhera to Present at the Bio€quity 2014 Conference

Liestal, Switzerland, May 15, 2014 – Santhera Pharmaceuticals (SIX: SANN) announced today that Thomas Meier, Chief Executive Officer of Santhera, will present at the upcoming Bio€quity Europe 2014 Conference in Amsterdam on Thursday, May 22, 2014, at 9.00 am. In the context of the recent filing of a Marketing Authorization Application (MAA) in the European Union (EU) for Raxone® in Leber's Hereditary Optic Neuropathy (LHON) and of the positive outcome for Santhera's Phase III trial in Duchenne Muscular Dystrophy (DMD), Dr. Meier will provide a pipeline overview and regulatory milestone and business outlook.

Slides will be available after the presentation for download on the Company's website www.santhera.com under *Investors/Presentations*.

Now celebrating its 15th meeting, Bio€quity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 600 leading European companies to thousands of investment and pharma business development professionals.

* * *

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases.

Santhera recently announced the re-filing of the MAA for LHON based on additional clinical efficacy data and following pre-filing advice from EU member states. The compound has been granted orphan drug designation in the EU and the US. Raxone® would become the first product authorized for the treatment of this rare, inherited disease which otherwise invariably leads to blindness. Santhera expects a decision from the European Medicines Agency in the first half of 2015. Earlier this year, the French National Agency for the Safety of Medicine and Health Products (ANSM)

granted a temporary authorization for use for Raxone® in LHON patients in France based on a data package comparable to the submitted MAA dossier.

On May 13, 2014, Santhera announced a positive outcome for its Phase III DELOS trial in DMD. The DELOS study randomized 65 DMD patients who were 10-18 years of age and who were not using concomitant corticosteroids. The study met the primary endpoint, the difference between Catena®/Raxone® and placebo in the change from baseline to week 52 in Peak Expiratory Flow (p=0.04). Peak Expiratory Flow is a measure of respiratory muscle strength, the decline of which is a major contributing factor to morbidity and mortality in DMD. Catena®/Raxone® (900 mg/day) was safe and well tolerated with adverse event rates comparable to placebo.

Santhera is collaborating with the National Institutes of Health on a placebo-controlled Phase II clinical trial for the treatment of primary progressive Multiple Sclerosis (ppMS), a currently untreatable disease affecting approximately 60,000 patients in North America and 85,000 in Europe.

Santhera holds full global patent and/or commercialization rights to all of its clinical development programs for Catena®/Raxone®. For further information, please visit the Company's website www.santhera.com.

For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
thomas.meier@santhera.com

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.